Order Article Reprints

Rosales M, Pérez GV, Ramón AC, Cruz Y, Rodríguez-Ulloa A, Besada V, Ramos Y, Vázquez-Blomquist D, Caballero E, Aguilar D, et al. Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines. 2021; 9(7):766. https://doi.org/10.3390/biomedicines9070766

Rosales, Mauro, George V. Pérez, Ailyn C. Ramón, Yiliam Cruz, Arielis Rodríguez-Ulloa, Vladimir Besada, Yassel Ramos, Dania Vázquez-Blomquist, Evelin Caballero, Daylen Aguilar, and et al. 2021. "Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300" Biomedicines 9, no. 7: 766. https://doi.org/10.3390/biomedicines9070766

Rosales, M., Pérez, G. V., Ramón, A. C., Cruz, Y., Rodríguez-Ulloa, A., Besada, V., Ramos, Y., Vázquez-Blomquist, D., Caballero, E., Aguilar, D., González, L. J., Zettl, K., Wiśniewski, J. R., Yang, K., Perera, Y., & Perea, S. E. (2021). Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300. Biomedicines, 9(7), 766. https://doi.org/10.3390/biomedicines9070766